Clinigen Group Further Strengthens Oncology Support Portfolio With Acquisition Of Ethyol® (Amifostine), From AstraZeneca PLC (AZN)
8/20/2014 11:04:24 AM
BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol® (amifostine) from AstraZeneca. Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by